Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool

May 17, 2021|

Mayo Clinic and AMC Amsterdam to Present Data on Predicting Progression to Esophageal Cancer in Barrett’s Esophagus Pittsburgh, Pennsylvania, May 17, 2021 (GLOBE NEWSWIRE) -- PITTSBURGH, Pennsylvania, May 17, 2021 – Cernostics (https://www.cernostics.com/) a pioneer in delivering spatialomics to the clinic, announced today that new results from clinical studies on the TissueCypher® Barrett’s Esophagus Assay will be presented at Digestive Disease Week® (DDW®) 2021 taking place May 21-23. Clinical Read More

Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE

June 25, 2020|

Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma   Pittsburgh, Penn., June 25, 2020 – Cernostics, a leader in the development of AI-driven image analysis technologies for precision medicine testing, today announced publication of new clinical results demonstrating further validation of how its TissueCypher® diagnostic test predicts fut Read More

Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE

March 3, 2020|

  First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high risk non-dysplastic BE patients that progress to EAC at rates higher than expert-confirmed LGD   Pittsburgh, Penn., March 3, 2020 ̵ Cernostics, a leader in the development of AI-driven image analysis technologies for precision medicine testing, today announced the publication of positive data from a blinded, independent validation study of its breakthrough TissueCypher® Barrett’s Esophagus Assay b Read More

TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

October 22, 2019|

Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett’s esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD)   PITTSBURGH, Penn., October 22, 2019 — Cernostics, developer of AI-driven image analysis solutions for pathology assessment of tissue biopsies, announced upcoming presentations at the American College of Gastroenterology (ACG) and the United European Gastroenterolo Read More

Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease

July 1, 2019|

  PITTSBURGH, Penn., July 1, 2019 — Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished medical advisory board (MAB) including key opinion leaders and world-renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer.   “Timing is right to bring together this world-class group of medical advisors to provide strategic insights into our evidence development and market Read More

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

May 8, 2019|

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay in determining the risk of progression to esophageal cancer (EC) in patients with Barrett’s esophagus (BE) will be presented during an oral session at Digestive Disease Week (DDW) 2019.   The study was conducted by clinicians at Cleveland Clinic and th Read More

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics

November 20, 2018|

– US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients – PITTSBURGH, Penn., November 20, 2018 — Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014.   Earlier this Read More

Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures

March 21, 2018|

– TissueCypher® Barrett’s Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Cancer –   PITTSBURGH, Penn., March 21 2018 — Cernostics, a privately-held company focused on delivering next-generation cancer diagnostics and prognostics, announced today that it has raised $2.5 million in Series A1 financing, led by Illumina Ventures. With this capital investment, Cernostics will be able to intensify its clinical and market development studies for the company’s Tis Read More

Cernostics Announces Leadership Team Expansion

September 22, 2017|

–  New Commercial Leader Positions Company for Continued Success and Growth   –   BETHLEHEM and PITTSBURGH, Penn. – September 12, 2017 – Cernostics, a privately-held diagnostics company focused on delivering next-generation cancer diagnostics and prognostics, announced today the appointment of Lisa Bichsel as Vice President of Marketing to continue development and growth for the company. Ms. Bichsel previously served as Vice President of Marketing for C2 Therapeutics and Commercial Marketin Read More

New TissueCypher® Validation Study Identifies High Risk Barrett’s Esophagus Patients Who are 46x More Likely to Have Cancer at Time of Biopsy

October 11, 2016|

Study indicates that TissueCypher® may detect a field effect associated with high grade dysplasia and cancer, which can be challenging to recognize with standard endoscopic and histologic surveillance   BETHLEHEM, PA. – A recent study published in the electronic issue (October) of the journal Cancer Epidemiology, Biomarkers and Prevention provides further validation to support the clinical use of TissueCypher® Barrett’s Esophagus Assay (TissueCypher®), developed by Cernostics, Inc., a leade Read More

UPMC Partners with Cernostics to Pursue ‘Precision Medicine’

August 31, 2016|

PITTSBURGH, PA – As part of its wide-ranging efforts to better target treatments to patients while reducing unnecessary tests and procedures, UPMC announced today that it is investing in and partnering with Cernostics, an oncology diagnostics company whose unique technology enables so-called “precision medicine.” Through UPMC Enterprises, the commercialization arm of UPMC, the health system is the lead investor in a $5 million round of funding by Cernostics to help it grow and accelerate its int Read More

Cernostics Announces Scientific Presentations at DDW and ISPOR Meetings Demonstrating Clinical Validation and Cost-Effectiveness of New TissueCypher® Barrett's Esophagus Assay

May 11, 2016|

Test Predicts Development of Esophageal Cancer in Patients with Barrett's Esophagus Bethlehem, PA -  Cernostics, Inc. today announced that findings from three scientific studies of its new TissueCypher® Barrett's Esophagus Assay will be presented at the Digestive Disease Week (DDW) meeting in San Diego. DDW is the world's largest conference on Gastro-intestinal Medicine and the ideal place for physicians to view data supporting the reliability and cost-effectiveness of Cernostics' TissueCypher® Read More

Ground-breaking Cancer Diagnostic Technology Receives Phase 2 SBIR Grant

October 9, 2015|

Grant will further validate Cernostics' diagnostic technology for predicting risk of future progression to esophageal cancer in patients with Barrett's Esophagus   PITTSBURGH, PA. – The National Institutes of Health have awarded Cernostics, a pioneer in delivering deeper tissue insights, a $1.2MM SBIR grant for its lead product, the TissueCypher™ Barrett's Esophagus Assay.   This grant funding will allow Cernostics to further validate their unique TissueCypher™ approach t Read More

Cernostics Announces Three Patents Addressing the TissueCypher® Technology Platform

February 11, 2014|

US and Japanese patents cover the Company's whole slide imaging and analysis platform, which simultaneously measures tumor, immune, and stromal cells, processes, and biomarkers  on a single specimen   PITTSBURGH, Pa. – Cernostics, a diagnostics company delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that the United States Patent and Trademark Office has issued two patents, US Patent 8,114,615 and US Patent 8,597,899, covering diffe Read More

Cernostics Collaborates with Prestigious Academic Medical Center in The Netherlands

January 7, 2014|

Collaboration will provide Cernostics with access to one of the largest Barrett's Esophagus patient registries in the world   PITTSBURGH, Pa. – Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that it is collaborating with the Academic Medical Center in The Netherlands (AMC).  As part of the collaboration, AMC will be providing Cernostics with access to one of the largest Barrett's Esopha Read More

Cernostics Raises $1.4 Million in Series B Round

December 3, 2013|

Funding will further develop a breakthrough diagnostic platform, producing comprehensive risk prediction for the development of esophageal cancer in patients with Barrett's Esophagus   PITTSBURGH, Pa. – Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis, announced today that it has raised $1.4 million in Series B funding.  Original investors participating in this round of funding include Nov Read More

Cernostics Announces New Scientific Advisors

April 14, 2013|

DANVILLE, Pa. – John M. Inadomi, M.D., the Cyrus E. Rubin Professor of Medicine, and Division Chief, Gastroenterology, at the University of Washington, and Robert F. Murphy, Ph.D., Ray and Stephanie Lane Professor of Computational Biology and Director of the Ray and Stephanie Lane Center for Computational Biology in the School of Computer Science at Carnegie Mellon University, will serve as scientific advisors to Cernostics.   They will assist Cernostics, a life science firm that develops a Read More

Cernostics receives $55,000 investment from Ben Franklin Technology Partners

March 12, 2012|

DANVILLE, Pa. – Cernostics, a life science firm that develops and commercializes advanced cancer diagnostic tests, has received a $55,000 investment from Ben Franklin Technology Partners of Northeastern Pennsylvania. The funding will be used to validate a diagnostic and prognostic test that predicts the risk of developing esophageal cancer in patients with Barrett's Esophagus.   "We are very pleased to receive this additional investment from Ben Franklin Technology Partners, which will help Read More

Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests

July 18, 2010|

(PITTSBURGH and DANVILLE, Pa). - Cernostics Inc., a biotechnology firm specializing in advanced cancer diagnostics, and Geisinger Health System, a $2.1 billion integrated health services organization, today announced a partnership in personalized healthcare. They will focus on developing diagnostic technologies that are based on detecting differences in the cellular and molecular make up of patient tissue samples. These technologies promise to more effectively predict disease progression and ide Read More

Cernostics, Geisinger to Partner on Personalized Healthcare

June 18, 2010|

(PITTSBURGH and DANVILLE, Pa). - Cernostics Inc., a biotechnology firm specializing in advanced cancer diagnostics, and Geisinger Health System, a $2.1 billion integrated health services organization, today announced a partnership in personalized healthcare. They will focus on developing diagnostic technologies that are based on detecting differences in the cellular and molecular make up of patient tissue samples. These technologies promise to more effectively predict disease progression and ide Read More